CLAVULANIC ACID DERIVATIVES, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS

Abstract: The compounds of the formula (I): and salts and cleavable esters thereof wherein X is a sulphur atom or SO or SO₂ group; have been found to be β-lactamase inhibitors and antibacterial agents. Their pre­ paration and use is described.

Description: CLAVULANIC ACID DERIVATIVES Their Preparation and Use This invention relates to novel antibiotics and ss-lactamase inhibitors and to processes for their production. Belgian Patent Specification Nos. 850779 and 851821 disclose that t1.ioethers derived from clavulanic acid and oxidation products of such thioethers possess P-lactamase inhibitory properties. It has now been found that one thioether and its oxidation products, and pharmaceutically acceptable salts and esters thereof are particularly effective as P-lactamase inhibitors for the protection of penicillins and cephalosporins from degradation in animals infected by ss-lactamase producing bacteria. The present invention provides the compounds of the formula (I): EMI1.1 and salts and cleavable esters thereof wherein X is a sulphur atom or a SO or SO2 group. Suitably X in the compound of the formula (I) is a sulphur atom. More suitably X in the compound of the formula (I) is SO. Preferably X in the compound of the formula (I) is S02. The compounds of the formula (I) are suitably provided in the form of the free-acid. The compounds of the formula (I) are aptly in the form of a salt. Although such salts are normally those which are pharmaceutically acceptable, salts with pharmaceutically unacceptable ions are also useful as they may serve as intermediates in the preparation of pharmaceutically acceptable salts by ion-exchange or in the preparation of cleavable esters. Examples of pharmaceutically acceptable salts of the compounds of the formula (I) include the alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium, and ammonium or substituted ammonium salts for example those with lower alkylamies such as triethylamine, hydroxy-lower alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine, tris-(hydroxymethyl)amine or tris-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylamine, N,N-dibenzylethylenediamine, l-ephenamine, N-ethylpiperidine, N-benzyl-P-phenethylamine, dehydroabietylamine or N,N'-bis-dehydroabietylethylenediamine. The lithium and t-butyl-amtnonium salts are useful as intermediates, for example as salts which are easily prepared and stored in solid form and which later may be converted into a pharmaceutically acceptable salt as previously described by ion-exchange. Thus suitable salts of this invention include the lithium, sodium, potassium, calcium, magnesium, ammonium and t-butylammonium salts. The sodium, potassium, calcium and magnesium salts are favoured pharmaceutically acceptable salts. Highly favoured compounds of this invention include salts of the compound of the formula (I) wherein X is a SO or S02 group. Preferred compounds of this invention include the pharmaceutically acceptable salts of the compound of the formula (I) wherein X is a S02 group. The salts of the compounds of the formula (I) are envisaged primarily as pharmaceutical agents although ttiey may also be employed as intermediates, for example in the preparation of other salts or in the preparation of the parent acid or in the preparation of esters. The compounds of the formula (I) may be provided in the form of cleavable esters. Suitable cleavable esters include those which serve as chemical intermediates by way of being cleavable by chemical means such as hydrogenolysis or mild base hydrolysis. Other suitable cleavable esters are those hydrolysable in-vivo to a compound of the formula (I) or its salt. Suitable esters of the compound of the formula (I) include those of the sub-formul a) a) and b): ----CO2A a) ----C02CHA A b) wherein A1 is an alkyl group of 1-6 carbon atoms optionally substituted by an alkoxyl or acyloxy group of 1-7 carbon atoms; A2 is an alkenyl group of up to 5 carbon atoms or is a phenyl group optionally substituted by a fluorine, chlorine or bromine atom, or a nitro or alkyl or alkoxyl group of up to 4 carbon atoms; and A3 is a hydrogen atom, an alkyl group of up to 4 carbon atoms or a phenyl group optionally substituted by a fluorine, chlorine or bromine atom, or a nitro or alkyl or alkoxyl group of up to 4 carbon atoms. Certain favoured groups A1 include the methyl, ethyl, propyl, methoxymethyl, methoxyethyl, acetoxymethyl, acetoxyethyl, phthalidyl, ethoxycarbonyloxymethyl, a-ethoxycarbonyloxyethyl, pivaloyloxymethyl and the like groups. Certain favoured groups A2 include the phenyl, methoxyphenyl and nitrophenyl groups. A particularly favoured moiety A3 is the hydrogen atom. Of these esters those favoured as in-vivo hydrolysable esters are the acetoxymethyl, acetoxyethyl, phthalidyl, ethoxycarbonyloxymethyl, a-ethoxycarbonyloxyethyl and pivaloyloxymethyl esters. The in-vivo hydrolysable nature of the ester may be confirmed by administration to an animal such as a mouse or rat and determination of the presence of a compound of the formula (I) or a salt thereof in the blood or urine of the animal. Alternatively hydrolysis in human blood or serum may be determined. The present invention also provides a pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof and a pharmaceutically acceptable carrier. Most suitably the composition of this invention will contain a pharmaceutically acceptable salt of a compound of the formula (I). Favourably said salt is of the compound of the formula (I) wherein X is SO and preferably said salt is of the compound of the formula (I) wherein X is SO. The compositions of this invention will generally contain from 25 mg to 500 mg of the compound of the invention but more usually from 50 mg to 250 mg of said compound, for example 75, 100, 125, 150, 175, 200 or 225 mg. The compositions may be administered orally or by injection from 1 to 6 times a day and more usually from 2 to 4 times a day. The usual daily dose for a 70 kg adult human will be in the range 80 mg to 800 mgs and more usually from 125 mg to 50 mg. Since the compounds of this invention have a degree of antibacterial activity in their own right they may be used to treat infections due to strains of Staphylococcus aureus, Escherichia coli, Klebsiella aerogenes, Proteus spp. and the like; for example they may be used to treat urinary tract infections due to such organisms or mastitis in cattle due to such organisms. However as has been previously indicated it is believed that the greatest usefulness of the compounds of the formula (I) and their pharmaceutically acceptable salts and in-vivo hydrolysable esters lies in their ability to inactivate bacterial P-lactamase and so enhance the in-vivo effectiveness of penicillins or cephalosporins. It is possible to administer the above described compositions to a mammal which is concurrently or consecutively also treated with a penicillin or cephalosporin. In this form of therapy the penicillin or cephalosporin is used in its conventional dosage. However for greater convenience and better control it is preferred to include the penicillin or cephalosporin in the same unit dose composition as the compound of the formula (I) or its pharmaceutically acceptable salt or in-vivo hydrolysable ester. Accordingly in a further aspect this invention provides a pharmaceutical composition which comprises a penicillin or cephalosporin, a compound of the formula (I) or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof and a pharmaceutically acceptable carrier. When used herein the term "penicillin" extends to the penicillin itself and to its pharmaceutically acceptable salts and pro-drugs. Similarly when used herein the term "cephalosporin" extends to the cephalosporin itself and to its pharmaceutically acceptable salts and pro-drugs. The synergistic composition may be adapted for oral or parenteral administration except of course if the penicillin or cephalosporin included is not one orally administrable, when the synergistic composition will be adapted for parenteral administration. British Patent Specifications Nos. 1508977 and 1508978 disclose suitable forms of synergistic composition and are incorporated herein by reference. By replacing the clavulanic acid or its salt or ester of said specifications by the compound of the formula (I) or its pharmaceutically acceptable salt or in-vivo hydrolysable ester, the desired composition of this invention results. Particularly favoured orally administrable synergistic compositions of this invention are those which comprise amoxycillin trihydrate equivalent to 100 mg to 1000 mg of arnoxycillin and the compound of the formula (I) wherein X is S02 or a pharmaceutically acceptable salt thereof equivalent to 50 nig to 500 mg of the compound of the formula (I) wherein X is S02. The present invention also provides a process for the preparation of a compound of the formula (I) as hereinbefore defined or a salt or cleavable ester thereof which process comprises the reaction of a cleavable ester of a compound of the formula (II): EMI8.1 wherein Y is a displaceable atom or group; with furfurylmercaptan to yield the cleavable ester of the compound of the formula (I) wherein X is a sulphur atom, and thereafter optionally performing one or more of the following steps: a) oxidising the sulphur atom to a SO or S02 group, b) cleaving the cleavable ester to yield the compound of the formula (I) or its salt, c) re-esterifying the compound of the formula (I) or its salt to form a cleavable ester. Suitable moieties Y include conventional displaceable groups such as sulphonate or carboxylate 1 1 1 O.CO.OR1 were 1 esters such as O.S02.R , O.CO.R or O.CO.OR where R is an inert organic group such as a lower alkyl group (such as a methyl, ethyl, propyl or butyl group) optionally substituted by one or more halogen atoms, a phenyl, benzyl, methoxyphenyl, methylphenyl, halophenyl, nitrophenyl or like group. Such displaceable groups may be displaced by furfurylmercaptan in the presence of a non-nucleophilic base, preferably 0.9-1.1 equivalents of such a base, and most preferably one equivalent. Suitably the non-nucleophilic base is triethylamine. Other suitable moieties Y are halogen atoms, for example a chlorine or bromine atom, which may be displaced by furfurylmercaptan in the presence of a non-nucleophilic base and/or silver oxide and/or a soluble silver salt preferably using 0.9-1.1 equivalents of such a base, and most preferably one equivalent. Suitably the non-nucleophilic base is triethylamine. A further suitable moiety Y is the hydroxyl group which may be displaced by furfurylmercaptan in the presence of an acid catalyst. Suitably the acid catalyst is a Lewis acid catalyst such as boron trifluoride or its chemical equivalent (such as boron trifluoride etherate). The thioetherification may be carried out at a non-extreme depressed or ambient temperature such as -600C to +200C, preferably from -300C to OOC. When the thioetherification reaction comprises inter alia a non-nucleophilic base for example triethylamine, the reaction solvent is most suitably dimethylformamide. When the thioetherification reaction comprises an acid catalyst for example boron trifluoride the reaction medium is suitably a non-hydroxylic solvent such as a hydrocarbon, halohydrocarbon or ester solvent, for example benzene, toluene, dichloromethane, ethyl acetate, chloroform, or mixtures thereof. Preferred values of Y when a non-nucleophilic base is used are a chlorine or bromine atom, or a dichloroacetoxy, mesyloxy, tosyloxy or phenylsulphonyloxy group. Particularly preferred is when Y is a dichloroacetoxy group. A preferred value of Y when an acid catalyst is used is when Y is a hydroxy group. Cleaving the cleavable ester of the compound of the formula (I) to form the parent acid or its salt may be achieved by hydrogenolysis, dissolving metal reduction or hydrolysis. Thus for example an ester such as a methyl, ethyl, methoxymethyl, ethoxymethyl or acetoxymethyl ester may be subjected to mild base hydrolysis to yield a salt of a compound of the formula (I). Suitably these esters may be hydrolysed by maintaining the pH of the medium at 7.5 to 9 until the hydrolysis -is effected. Most suitably a readily hydrolysable ester such as the methoxymethyl ester is employed in this process. The pH may be maintained in the desired range in a pH-stat by the addition of a solution of suspension of a base such as LiOH, NaOH, KOH, Ca(OH)2, Mg(OH)2, NaHC03, Na2C03, MgC03 or the like at a rate that prevents the accumulation of excess base which would cause the pH to increase unacceptably. Dissolving metal reduction may be carried out using iron/ammonium chloride systems; but is not favoured for sulphoxides. Suitable methods of hydrogenolysis of esters of the compounds of formula (I) include hydrogenation in the presence of a transition metal catalyst. Suitable hydrogenolysable esters of the compound of the formula (I) include those where the ester moiety is of the sub-forinula CO2CH2A3 as hereinbefore defined and of these the benzyl and p-methoxybenzyl esters are particularly suitable. The p-nitrobenzyl ester is a preferred ester. The pressure of hydrogen used in the reaction may be low, medium or high but in general an approximately atmospheric or slightly superatmospheric pressure of hydrogen is preferred. The transition metal catalyst employed is preferably palladium, for example palladium on charcoal, palladium on barium sulphate, palladium on calcium carbonate or the like. The hydrogenation may be effected in any convenient solvent in which the ester is soluble such as tetrahydrofuran, ethyl acetate, ethanol, aqueous ethanol or the like. If this hydrogenation is carried out in the presence of a base then a salt of the compound ,l ic,imilaa (I) is produced. Suitable bases for inclusion include NaHC03, Na2C03, K2CO3, CaC03, MgC03, LiHCO3 and the like. If no base is present then hydrogenation leads to the preparation of an acid of formula (I) which may then be neutralised if desired to yield a salt. Suitable bases for such neutralisation include LiOH, NaHC03, KOH, Ca(OH)2, Ba(OH)2, Mg(OH)2, NH40H, N(C2H5)3, Na ethylhexanoate, K ethylhexanoate and the like e.g. MgO and NH2C (CH3)3. The lithium salts of the compounds of formula (I) tend to be more easily prepared in pure crystalline for than other salts of the compounds of formula (I). It is therefore often convenient to first form the lithium salt and then convert this into a further salt by ion-exchange, for example by passing a solution of the lithium salt through a bed of cation exchange resin in sodium, potassium, calcium, ammonium or like form. Suitable cation exchange resins include Amberlite IR 120 and equivalent resins. Another salt suitable for. use as an intermediate in this way is the t-butylamine salt. Oxidation of a compound of the formula (I) or a salt or cleavable ester thereof wherein X is a sulphur atom may be effected by reaction with an organic per acid such as peracetic acid, metaperiodic acid and m-chloroperbenzoic acid. Normally one equivalent of the acid is used for oxidation to the sulfoxide level whereas two or more equivalents are used for oxidation to the sulfone level. The reaction is generally carried out at a depressed temperature which may conveniently be at about 00. Suitable solvents are inert organic solvents such as dichloromethane and chloroform. In a further aspect of this invention there is provided a process for the preparation of a compound of the formula (I) as hereinbefore defined or a salt or cleavable ester thereof which process comprises the reaction of a cleavable ester of clavulanic acid with a compound of the formula (III): EMI14.1 and a compound of the formula (IV): EMI14.2 in which R1 and R2 are moieties such that the compound of the formula (III) is a sulphenimide; R3, R4 and R5 are groups such that the compound of the formula (IV) is a phosphine; and thereafter if desired: a) oxidising the sulphur atom to a SO or S02 group, b) cleaving the cleavable ester to yield the compound of the formula (I) or its salt, c) re-esterifying the compound of the formula (I) or its salt to form a cleavable ester. The groups R1 and R2 will normally be selected from hydrocarbon groups which may be linked together. Particularly apt groups R1 and R2 include lower alkyl groups optionally linked to form part of a 5- or 6membered ring. Preferred compounds of the formula (II) include those of the formulae (V) and (VI): EMI15.1 The compound of the formula (V) is particularly suitable as a by-product of the reaction is water-soluble and may thus be readily removed by washing with water. Suitable values for R3, R and R include hydrocarbon groups of up to 7 carbon atoms and hydrocarbon groups substituted by a group of the sub-formulae OR or O.CO.R6 where R6 is a lower alkyl group. Most suitably R3, R4 and R5 each have the same meaning. Favoured values for R , R4 and iz include methyl, ethyl, n-propyl, n-butyl, phenyl, 4-methoxyphenyl and benzyl. A particularly suitable compound of the formula is tri-n-butyl-phosphine. The reaction of a cleavable ester of clavulanic acid and the compounds of the. formulae (III) and (IV), may take place at any convenient non-extreme temperature, for example -100C to 500C, more usually Oo to 400C, generally 100 to 300C and very conveniently at ambient (about 15-250C). The reaction is generally carried out in an aprotic medium. Suitable solvents include hydrocarbon solvents such as benzene, toluene and the like. If desired the reaction may be carried out under an inert gas such as nitrogen. Once the reaction is complete, for example as indicated by tlc, the mixture may be washed with water to remove the water-soluble products, and the organic layer dried and evaporated. The initial product may be further purified by chromatography if desired, for example over silica eluting with ethyl acetate/petroleum ether or the like. Once formed the ester of the thioether may optionally be oxidised and/or converted to the corresponding acid or salt or to another ester in conventional manner. The following Examples illustrate the invention. Example 1 p-Nitrobenzyl 9-(2'-furylmethylthio)-9-deoxyclavulanate EMI17.1 p-Nitrobenzyl clavulanate (el) (2 g) was dissolved in methylene dichloride (100 ml) and cooled to -300C under N2. Boron trifluoride-etherate (0.36 ml) was added at -30 followed by a solution of furfurylmercaptan (0.62 ml) in methylene chloride (10 ml). The mixture was stirred under nitrogen at -10 for 2 hr. and washed with 3% sodium bicarbonate solution (2 x 100 ml) and water (50 ml). The organic phase was dried over anhydrous magnesium sulphate and the solvent evaporated to give an oil which after chromatography on silica-gel using ethyl acetate - petrol 1:3 as eluent gave p-nitrobenzyl-9 (2'-furylmethylthio)-9-deoxyclavulanate (e2) as an oil (449 mg). [&alpha;]D20 + 21.10 (c. 1.8; CHCl3); may (CHC13) D mg). max 3 1805, 1755 and 1692 cm ; #max (EtOH) 217 (22,500) and max 267.5 (11,150) nm: 6 (CDC13) 3.03 (111, d, J 17 Hz, 6ss-CH), 3.22 (2H, d, J 8 Hz, 9-CH2), 3.49 (1H, dd, J 17 and 2.5 Hz, 6a-CH), 3.60 (2H, s, -SCH2-Ar), 4.70 (1H, br.t, J 8 Hz, 8-CH), 5.10 (1H, s, 3-CH), 5.26 (2H, s, -0CH2Ar), 5.65 (1H, d, J 2.5 Hz, 5-CH), 6.0-6.4 (2H, m, furyl 3H and 4H), 7.2-7.4 (1H, m, furyl 5-CH), 7.49 and 8.20 (4H, 2d, Ar-H). Example 2 Lithium 9-(2' -furylmethylthio) -9-deoxyclavulanate EMI18.1 A solution of p-nitrobenzyl 9-(2'-furylmethylthio)9-deoxyclavulanate (e2) (.35 g, .81 mmole) in tetrahydrofuran (50 ml) was added to a pre-hydrogenated suspension of 10% Pd/C in tetrahydrofuran (50 ml). The mixture was hydrogenated at 1 atmosphere for 1i hours, filtered through celite and the filtrate evaporated to 10 ml. At this point the solution contained 9-(2'-furylmethylthio)-9-deoxyclavulanic acid (e3). A solution of lithium carbonate (.03 g, .405 mmole) in water (20 ml) was added with stirring and the resulting solution extracted with ethyl acetate (3 x 20 ml), acidified to pH 2.5 with 1N hydrochloric acid and extracted with ethyl acetate (3 x 20 ml), The latter ethyl acetate extracts were dried over MgS04 and evaporated. The residue was taken up in 10 ml tetrahydrofuran, 10 ml water added and treated with .lN aqueous lithium carbonate to bring the pH to 7. The organic solvent was evaporated and the remaining aqueous solution freeze dried to provide lithium 9-(2'-furylmethylthio)-9-deoxyclavulanate (e4) (.122 g, 50%). [&alpha;]D 20 + 60.2 (c. 1.0; H20); max (KBr) 1765, 1690 and 1615 cm ; Amax (H20) 201 nm (15150) and 222 nm (14850); # (D20 - HOD at 4.61) 3.00 (1H, d, J 17 Hz, 6ss-CH), 3.20 (2H, d, J 8 Hz, 9-CH2), 3.52 (1H, dd, J 17 and 2.5 Hz, 6&alpha;-CH), 3.71 (2H, s, -SCH2Ar), 4.72 (1H, broad t, J 8 Hz, 8-CH), 4.87 (1H, s, 3-CH), 5.64 (1H, d, J 2.5 Hz, 5-CH), 6.2-6.5 (2H, m, furan 3-H and 4-H), 7.4-7.5 (1H, m, furan 5-H). Example 3 p-Nitrobenzyl 9-(2'-furylmethylsulfonyl)-9-deoxyclavulanate EMI20.1 A solution of p-nitrobenzyl 9-(2'-furylmethylthio)9-deoxyclavulanate (e2) (1.20 g, 2.78 mmole) in 50 ml dichloromethane was ice cooled and treated dropwise with a solution of m-chloroperbenzoic acid (1.33 g, 7.73 mmole) in dichloromethane (20 ml). The mixture was stirred 2 hour1 washed with saturated aqueous sodium bicarbonate (2 x 50 ml) and water (50 ml), dried over MgS04 and evaporated. The residue was chromatographed on silica, eluting with ethyl acetate/petrol 4:6, to yield p-nitrobenzyl 9-(2'-furylmethylsulfonyl)-9-deoxyclavulanate (e5) (.95 g, 73%) as a white foam. [&alpha;]20 D + 10.3 (c. 1.1; CHC13); v (CHC13) 1810, 1760 and 1695 cm ; Amax (EtOH) 224 nm (s) (23400) and 263 nm (13280); 6 (CDC13) 3.09 (1H, d, J 17 Hz, 66-CH), 3.3-3.9 (3H, m, 6a-CH and 9-CH2), 4.22 (2H,S-S0,CH2), 4.78 (lH, t, J 8 Hz, 8-CH), 5.18 (1H, s, 3-CH), 5.27 (2H, s, -0CH2Ar), 5.74 (1H, d, J 2.5 Hz, 5-CH), 6.2-6.5 (2H, m, furyl 3-H and 4-H), 7.2-7.6 (3H, m, furyl 5-H and 2 Ar-H of p-nitrobenzyl,), 8.19 (211, d, 2 Ar-H of p-nitrobenzyl). Example 4 Lithium 9- (2 ' -furylmethylsulfonyl) -9-deoxyclavulanate EMI21.1 A solution of p-nitrobenzyl 9-(2'-furylmethylsulfonyl)-9-deoxyclavulanate (e5) (.95 g, 2.04 mmole) in tetrahydrofuran (100 ml) was added to a pre-hydrogenated suspension of 10% Pd/C (1 g) in tetrahydrofuran (20 ml). The mixture was hydrogenated at 1 atmosphere for 20 mins, filtered through celite and the filtrate evaporated to 10 ml to yield a solution of 9-(2'-furylmethylsulfonyl)9-deoxyclavulanic acid (e6). A solution of lithium carbonate (0.075 g, 1.02 mmole) in water (100 ml) was added and the solution extracted with ethyl acetate (3 x 50 ml), adjusted to pH 7 with 1N hydrochloric acid and freeze dried to yield lithium 9-(2'-furylmethylsulfonyl)-9-deoxyclavulanate (e7) (.60 g, 87%) as a white solid. [&alpha;]D20 + 33.7 (c. 1.0; H20); vmax (KBr) 1780, 1690 and 1620 cm . Xmax (H20) 206 nm (s) (13740) and 224 nm (15080); 6 (D20 - HOD at 4.61) 3.10 (1H, d, J 17 Hz, 66-CH), 3.59 (1H, dd, J 17 and 2.5 Hz, 6a-CH), 4.01 (2H, d, J 8 Hz, 9-CH2), 5.00 (1H, s, 3-CH), 5.76 (1H, d, J 2.5 Hz, 5-CH), 6.3-6.7 (2H, m, furyl 3-H and 4-H), 7.4-7.6 (1H, m, furyl 5-H). 8-CH and -SO2C2 obscured by HOD. Example 5 p-Nitrobenzyl 9-(2'-furylmethylsulfinyl)-9-deoxyclavulanate EMI23.1 A stirred, ice cooled solution of p-nitrobenzyl 9-(2'-furylmethylthio)-9-deoxyclavulanate (e2) (.375 g .87 mmole) in dichloromethane (25 ml) was treated over 5 mins dropwise with a solution of m-chloroperbenzoic acid (.150 g .87 mmole) in dichloromethane (10 ml). The solution was stirred 1¸ hrs. washed with aqueous 1N sodium bicarbonate solution (2 x 40 ml) and water (40 ml), dried over MgS04 and evaporated. The residue was chromatographed on silica (30 g), eluting with ethyl acetate to provide p-nitrobenzyl-(2'-furylmethylsulfinyl)- 9-deoxyclavulanate (e8) (.29 g, 74%) as a colourless oil. [a]20+ 6.00 (c. 1.0; CHC1 ); may (CHC13) 1810, 1755 and 1690 cm -1; #max (EtOH) 230 nm (s) (19270) and 260 nm (s) (10040); 6(CDC13) 3.09 (1H, d, J 17 Hz, 6ss-CH), 3.3-3.7 (3H, m, 6a-CH and 9-CH2), 3.92 and 3.97 (2H, 2s-CH2-furyl), 4.84 (1H, broad t, J 8Hz, 8-CH), 5.20 (1H, s, 3-CH), 5.28 (2H, s, -0CH2Ar), 5.72 (1H, d, J 2.5 Hz, 5-CH), 6.3-6.5 (2H, m, furyl 3-H and 4-Ei), 7.37.6 (3H, m, furyl 5-H and 2 p-nitrophenyl-H), 8.20 (2H, d, 2 p-nitrophenyl-H). Example 6 Lithium 9- (2' -furylmethylsulfinyl) -9-deoxyclavulanate EMI24.1 A solution of p-nitrobenzyl 9-(2'-furymethyl- sulfinyl)-9-deoxyclavulanate (.250 g .56 mole) in tetrahydrofuran (50 ml) was added to a pre-hydrogenated suspension of 10% Pd/C (.40 g) in tetrahydrofuran (50 ml) and hydrogenation at 1 atmosphere continued for lihrs. The mixture was filtered through celite and the filtrate evaporated to 10 ml to yield a solution of 9-(2'-furyl methylsulfinyl)-9-deoxyclawsulanic acid (e9). Water (10 ml) was added, followed by .1M aqueous lithium carbonate solution (2.8 ml), and the solution was washed with ethyl acetate (3 x 20 ml) , saturated with sodium chloride, acidified to pH 2.5 with 1N hydrochloric acid and extracted with ethyl acetate (3 x- 20 ml). The combined extracts were dried over MgS04 and evaporated and the residue taken up in tetrahydrofuran (10 ml). Water (10 ml) was added and the solution brought to pH 7 with .1M aqueous lithium carbonate solution. Organic solvent was removed by evaporation water reduced pressure and the aqueous solution freeze dried to yield lithium 9-(2'-furylmethylsulfinyl)-9-deoxyclavulanate (elO) (.133 g, 75%) as a yellow solid. [&alpha;]D20 + 23.20 (c. 1.2; H20), , #max (KBr) L785, 1685 and 1620 cm-1 X (H2O) 205 nm (s) (14670) and 231 nm (18100); max 2 6 (D20 - HOD at 4.61) 3.07 (1H, d, J 17 Hz, 6ss-CH), 3.33.8 (3H, m, 6&alpha;-CH and 9-CH2), 4.05 and 4.30 (2H, 2 parts of ABq, JAB 14.5 Hz, -CH2-furyl), 4.77 (1H, t, J 8 Hz, 8-CH), 5.00 (1H, s, 3-CH) , 5.73 (1H, d, J 2.5 Hz, 5-CH), 6.49 (2H, broad s, furyl 3H and 4H), 7.55 (1H, broad s, furyl 5-H). Example 7 Sodium 9-(2'-furylmethylsulfonyl)-9-deoxyclavulanate EMI26.1 A solution of p-nitrobenzyl 9-(2'-furylmethylsulfonyl)-9-deoxy clavulanate (1.14g 2.46 mmole) in tetrahydrofuran (50 ml) was added to a pre-hydrogenated suspension of 10% Pd/C (1.2g) in tetrahydrofuran (50 ml) and hydrogenation continued for 30 mins at 1 atmosphere. The mixture was filtered through celite and the filtrate evaporated under reduced pressure to approx. 10 ml, ice cooled and stirred, and treated with a solution of sodium bicarbonate (.206g 2.46 mmole) in 50 ml water. The resulting mixture was washed with ethyl acetate (3 x 50 ml), adjusted to pH 7 with .1N hydrochloric acid and freeze dried to provide sodium 9-(2'-furylmethylsulfonyl)-9-deoxyclavulanate (ell) (.73g, 85%) as a pale yellow solid. ; + 30.40 (c.l.l;H20); vmax (KBr) 1785, 1690 cm¯l; D max X max (H2 0) 210 nm (s) (12020) and 227 nm (13640); 6 (D20-MeCN=2.00) 3.06 (1H, d, J 17.5 Hz, 6ss-CH), 3.53 (1H, dd, J 17.5 and 2.5 Hz, 6a-CH), 3.97 (2H, d, J 8Hz, 9-CH2), 4.56 (2H, s, -CH2 furyl), 4.73 (lH, t, J 8Hz, 8-CH), 4.98 (1H, s, 3-CH), 5.73 (1H, d, J 2.5 Hz, 5-CH), 6.4-6.6 (2H, m, furyl 3-H and 4-H),7.5--.6 (1H,m, furyl 5-H). Example 8 p-Nitrobenzyl 9- (2' -furylmethylthio) -9-deoxyclavulanate EMI27.1 Tri-n-butyl phosphine (.215 ml .87 mmole) and p-nitrobenzyl clavulanate (el) (.167 g .50 nmole) were dissolved in tetrahydrofuran (5 ml) under nitrogen and treated with N-furfurylthio succinimide (.184 g .87 mmole) portion wise over 20 mins. The solution was diluted with ethyl acetate (20 ml), washed with water (2 x 20 ml), dried over MgSO4 and evaporated. Chromatography of the residue on silica (15 g) eluting with ethyl acetate/ petrol 1:4 provided p-nitrobenzyl 9-(2'-furylmethylthio)9-deoxy clavulanate (e2) (0.056g, 26%) as an oil. Example 9 p-Nitrobenzyl-9- (2 Lfurylmethylthio )-9-deoxyclavulanate A solution of p-nitrobenzyl -9-0- dichloroacety clavulanate (0.446 g) and furfurylmercaptan (0.2 ml) in dimethylformamide (10 ml) was cooled to -500C, triethylamine (0.14 ml) in dimethylformamide (5 ml) was added dropwise with stirring and the reaction mixture was allowed to warm to OOC. The mixture was diluted with ethyl acetate (100 ml), washed with water (100 ml), dilute hydrochloric acid (50 ml), water (100 ml), dried over anhydrous magnesium sulphate and evaporated in vacuo. The residue was chromatographed on silica using ethyl acetate/petrol 1:4 as eluant to provide the title ester as an oil (0.22 g; 53%), identical in all respects to Example 1. Example 10 Composition a. Amoxycillin trihydrate (equivalent to 250 mg of amoxycillin) sodium 9-(2'-furylmethylsulfonyl) -9- deoxyclavulanate (equivalent to 125 mg of 9-(2'furylmethylsulfonyl)-9-deoxyclavulanic acid) are filled into a two part gelatin capsule. b. Sodium amoxycillin (equivalent to 250 mg of amoxycillin) and sodium 9-(2'-furylmethylsulfonyl)-9deoxyclavulanate (equivalent to 125 mg of 9-(2' furylmethyl-sulfonyl)-9-deoxyclavulanic acid) were dissolved in 2 ml of sterile water for injection B.P. to yield a solution suitable for injection. Compositions such as those described above and other synergistic compositions of this invention may be used to treat infections due to strains of Staphyloccocus aureus, Klebsiella aerogenes, E. coli, Proteus spp., Bacteriodes spp., Haemophilus influenza, Neisseria gonorrhoeae and the like. Description 1 N-Furylthiosuccinimide A solution of furfuryl mercaptan (5.7g) in benzene (100 ml) was treated with 50 g Merck basic aluminium oxid (70-230 mesh) and stirred 24 hrs. with air bubbling through. The suspension was filtered and the filtrate evaporated to leave furfuryl disulfide as a reddish oil. A solution of furfuryl disulfide (3.43 g .0152 mole) in carbon tetrachloride (10 ml) was ice cooled and treated dropwise with a solution of chlorine (1.08 g .0152 mole) in carbon tetrachloride (15 ml). The resulting solution was added dropwise over 15 mins to a solution of succinimide (3.01 g .0304 mole) and triethylamine (4.58 ml .033 mole) in dimethylformamide (30 ml), and the mixture stirred 1 hour, diluted with ethyl acetate (300 ml), washed with water (2 x 100 ml), dried over MgS04 and evaporated. The residue was chromatographed on silica (50 g) eluting with ethyl acetate/petrol (1:1), and the required compound crystallised from ethyl acetate (.65 g), Prisms, m.p. 124-70C, vmax (CH 1730 -1 max Cl3) 1730 Cm 6 (CDCl3) 2.73 (4H, s, -CH2CH2-), 4.08 (2H, s, -SCH2-), 6.1-6.4 (2H, m, furyl 3-H and 4-H), 7.3-7.5 (lH, m, furyl 5-H); Found: C, 51.2; H, 4.2; N, 6.6, S, 15.2% CgHgN03S requires C, 51.2, H, 4.3, N, 6.6, S, 15.2%. Description 2 Pharmacology The compound of Example 7 was found to reduce the CD30 of amoxycillin from > 1000 mg/kg to 6.4 mg/kg in mice infected intra peritoneally with a plasmid carrying ss-lactamase producing strain of E.coli with oral dosing at 1,3 and 5 hour past infection using 20 mg/kg of said compound of Example 5 . Under similar conditions the analogous compound containing a phenyl ring in place of the furyl ring only reduced the CD50 of amoxycillin to about 100 mg/kg. When administered sub-cutaneously at 1 and 5 hours past infection the compound of Examples 4 and 6 reduced the CD50 values of amoxycillin to 6.6 and 15 mg/kg respectively in the above infection using 2 mg/kg of said compound of Examples 4 and 6. No drug induced toxic effects were noted in the test animals at the therapeutic dose.

Claims: WHAT WE CLAIM IS: 1. A compound of tulle formula (I): EMI32.1 or a salt or cleavable ester thereof wherein X is a sulphur atom or a SO or S02 group. 2 A compound as claimed in claim 1 wherein X is a S02 group. 3. A compound as claimed in any of claims 1 to 2 in the form of a pharmaceutically acceptable salt. 4. A compound as claimed in claim 3 in the form of a sodium, potassium, calcium or magnesium salt. 5. A compound as claimed in any of claims 1 to 2 in the form of an acetoxymethyl, acetoxyethyl, phthalidyl, ethoxycarbonyloxymethyl, a-ethoxycarbonyloxyethyl or pivaloyloxymethyl ester. 6. A pharmaceutical composition which comprises a compound as claimed in claim 1 and a pharmaceutically acceptable carrier therefor. 7. A pharmaceutical composition as claimed in claim 6 which also comprises a penicillin or cephalosporin. 8. A process for the preparation of a compound as claimed in claim 1 which prc,cess comprises the reaction of a cleavable ester of a compound of the formula (II): EMI33.1 wherein Y is a displaceable atom or group; with furfurylmercaptan to yield the cleavable ester of the compound of the formula (I) wherein X is a sulphur atom, and thereafter optionally performing one or more the followinc steps: a) oxidising the sulphur atom to a SO or S02 group, b) cleaving the cleavable ester to yield the compound of the formula (I) or its salt, c) re-esterifying the compound of the formula (I) or its salt to form a cleavable ester 9. A process for the preparation of a compound as claimed in claim 1 which process comprises the reaction of a cleavable ester of clavulanic acid with a compound of the formula (III): EMI34.1 and a compound of the formula (IV): EMI34.2 in which R1 and R2 are nloieties such that the compound of the formula (III) is a sulphenimide; R3, R4 and R5 are groups such that the compound of the formula (1V) is a phosphine and Ie thereafter i@ desired: a) oxidising the sulphur atom to a SO or S02 group, b) cleaving the cleavable ester to yield tie compound of the formula (I) or its salt, c) re-esterifying the compound of tl-le formula (I) or its salt to form a cleavable ester. WHAT WE CLAIM IS: 1. A process for the preparation of a compound of the formula (I): EMI35.1 or a salt or cleavable ester thereof wherein X is a sulphur atom or a SO or S02 group, which process comprises the reaction of a cleavable ester of a compound of the formula (II): EMI35.2 wherein Y is a displaceable atom or group, with furfurylmercaptan to yield the cleavable ester of the compound of the formula (I) wherein X is a sulphur atom, and thereafter optionally performing one or more the following steps: a) oxidising the sulphur atom to a SO or S02 group, b) cleaving the cleavable ester to yield the compound of the formula (I) or its salt, c) re-esterifying the compound of the formula (I) or its salt to form a cleavable ester. 2. A process for the preparation of a compound of the formula (I): EMI36.1 or a salt or cleavable ester thereof wherein X is a sulphur atom or a sulphur atom or a SO or S02 group, which process comprises the reaction of a cleavable ester of clavulanic acid with a compound of the formula (III): EMI36.2 and a compound of the formula (IV): EMI36.3 in which R1 and R2 are moieties such that the compound of the formula (III) is a sulphenimide; R3, R4 and R5 are groups such that the compound of the formula (IV) is a phosphine; and thereafter if desired: a) oxidising the sulphur atom to a SO or S02 group, b) cleaving the cleavable ester to yield the compound of the formula (I) or its salt, c) re-esterifyiny the compound of the formula (I) or its salt to form a cleavable ester. 3. A process as claimed in either claim 1 or claim 2 adapted to the preparation of a compounds the formula (I) wherein X is a 5 2 group. 4. A process as claimed in any of claims 1 to 3 adapted to the preparation of a compound of the formula (I) in the form of a pharmaceutically acceptable salt. 5. A process as claimed in claim 4 adapted to the preparation of a sodium, potassium, calcium or magnesium salt. 6. A process as claimed in either claim 1 or claim 2 adapted to the preparation of a compound of the formula (I) in the form of an acetoxymethyl, acetoxyethyl, phthalidyl, ethoxycarbonyloxymethyl, -ethoxycarbonyloxyethyl or pivaloyloxymethyl ester.

Inventors: DAVIES, JOHN SYDNEY, HUNTER, PAMELA ANN
Applicants: BEECHAM GROUP PLC
Application year: 1980
Main classification: C07D498
IPC codes: A61K31, A61P31, C07D503